一个开放的标签研究的辅助德克斯特罗米多芬/昆在治疗耐药抑郁症
Philip R Wang1, Mani Yavi, Holim Lee
1From the Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD.
Journal of clinical psychopharmacology
|September 8, 2023
概括
在一项试点研究中,辅助德克斯特罗米多芬/氨酸 (DM/Q) 在47%的耐治疗抑郁症患者中显示出抗抑郁作用. 这种新疗法耐受性很好,这表明TRD管理的潜力.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 神经科学是一个神经科学.
背景情况:
- 耐治疗性抑郁症 (TRD) 影响大约三分之一的大型抑郁症患者.
- 谷氨酸调节剂,如胺,提供快速抗抑郁作用,但有局限性.
- 德克斯特罗米多芬/氨酸 (DM/Q) 作为TRD的辅助治疗正在探索中.
研究的目的:
- 在TRD患者中评估辅助德克斯特罗米多芬/昆丁 (DM/Q) 的抗抑郁疗效.
- 在这个患者群体中评估DM/Q的安全性和耐受性.
主要方法:
- 一项开放式试点研究涉及17名TRD住院患者.
- 参与者每天多达三次接受辅助的开放式DM/Q (20mg/10mg).
- 抑郁症的严重程度使用蒙哥马利-阿斯伯格抑郁症评分表 (MADRS) 评分进行评估.
主要成果:
- 47%的参与者对DM/Q做出了反应,12%的参与者获得了完全反应,35%的参与者获得了部分反应.
- 停药或出院后,MADRS评分的平均降低为-15.9%.
- DM/Q耐受性良好,有24%的人经历了不严重的不良事件,没有报告严重的不良事件.
结论:
- 在这项试点研究中,辅助DM/Q在47%的TRD患者中显示出抗抑郁药的有效性.
- 治疗耐受性很好,这表明了有利的安全性.
- 需要进行更大规模的安慰剂对照试验,以确认DM/Q对TRD的实际疗效.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
270
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
270
Sedatives and Hypnotics Drugs: Miscellaneous Agents
200
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
200
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
431
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
431
Drug Therapy
68
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
68
Electroconvulsive Therapy
68
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
68
Drugs for Treatment of Diarrhea-Predominant IBS
204
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
204


